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This report describes unique presentations of inclusion 
body myositis (IBM) in two unrelated patients, one male and 
one female, with genetically and histologically confirmed 
fragile X-associated tremor/ataxia syndrome (FXTAS). We 
summarize overlapping symptoms between two disorders, 
clinical course, and histopathological analyses of the two 
patients with FXTAS and sporadic IBM, clinically defined per 
diagnostic criteria of the European Neuromuscular Cen-
tre. In case 1, a post-mortem analysis of available brain and 
muscle tissues is also described. Histopathological features 
(rimmed vacuoles) consistent with clinically defined IBM 
were detected in both presented cases. Postmortem test-
ing in case 1 revealed the presence of an FMR1 premutation 
allele of 60 CGG repeats in both brain and skeletal muscle 
samples. Case 2 was a premutation carrier with 71 CGG re-
peats who had a son with FXS. Given that FXTAS is asso-
ciated with immune-mediated disorders among premuta-
tion carriers, it is likely that the pathogeneses of IBM and 
FXTAS are linked. This is, to our knowledge, the first report of 
these two conditions presenting together, which expands 
our understanding of clinical symptoms and unusual pres-
entations in patients with FXTAS. Following detection of a 
premutation allele of the FMR1 gene, FXTAS patients with 
severe muscle pain should be assessed for IBM.
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Fragile X syndrome (FXS) is a neurodevelopmental disor-
der caused by expansions of a CGG trinucleotide repeat 
element within the 5′ non-coding region of the fragile X 
mental retardation 1 (FMR1) gene (1,2). Full mutation alleles 
(>200 CGG repeats) generally result in a complete deficit 
of FMR1 protein (FMRP) (3,4). Fragile X-associated tremor 
ataxia syndrome (FXTAS) is characterized by white matter 
changes with generalized brain atrophy and the presence 
of spherical intranuclear inclusions in neurons and astro-
cytes (5,6). Clinically, FXTAS presents by the core features 
of gait ataxia and intention tremor, neuropathy, psychiatric 
problems, and cognitive impairment that includes execu-
tive dysfunction and memory deficits leading to dementia 
in approximately 50% of males (7,8).
Inclusion body myositis (IBM) is a form of idiopathic inflam-
matory myopathy, which generally develops in adults over 
the age of 50 years, with higher prevalence in males. IBM is 
unresponsive to immunosuppressive therapy, which differ-
entiates it from the other myopathies (9,10). IBM is character-
ized by insidious clinical onset of slowly progressive, usually 
asymmetric, proximal and distal muscle weakness. Clinical 
diagnosis of IBM is obtained by muscle biopsy with determi-
nation of clinical laboratory features, electromyography, and 
magnetic resonance imaging (MRI) of muscles (10). Current-
ly, there is no curative treatment for FXTAS or IBM (11-13).
Although FXTAS and IBM may have similarities in clinical pre-
sentations, these two conditions were not previously report-
ed to occur simultaneously in the same patient. Here we de-
scribe two cases of genetically and histologically confirmed 
FXTAS with a concomitant clinical diagnosis of IBM.
CASE REPORT 1
Patient 1, a Caucasian male, US Air Force WWII veteran pilot 
and a retired physician, presented at age 75 with a slight 
foot drop, which progressed to ataxia and falling with no 
tremor (Table 1). Spinal MRI was normal at that time, as 
were metabolic, endocrine and heavy metal poisoning 
peripheral venous blood analyses, suggesting a primary 
motor neuron disease. At 77 years of age, the patient un-
derwent a total hip replacement under general anesthesia. 
The patient continued to have progressive lower extremity 
weakness and he developed upper extremity weakness af-
ter his surgery. At 79 years of age, the patient had another 
total hip replacement, followed a year later by a shoulder 
replacement. A muscle biopsy was performed, along with 
electron microscopy, which was inconclusive upon review 
by muscle pathologists. Upon evaluation by a neurologist 
and a rheumatologist, the patient was clinically diagnosed 
with IBM (Clinically Defined IBM per European Neuromus-
cular Centre diagnostic criteria) (14). He was reported to 
have serum creatine kinase (CK) levels that reached 1800 
U/L (normal <171 U/L). The following year, the patient was 
suspected to have had a septic embolic stroke after falling 
and sustaining an open ankle fracture. By this point in time, 
the patient had become confined to bed because of sig-
nificantly progressive weakness and ataxia. The patient did 
not present with tremor. The family reports no intellectual 
or cognitive decline. He died at the age 88 from respira-
tory failure.
Postmortem testing revealed the presence of an FMR1 pre-
mutation allele of 60 CGG repeats in both skeletal muscle 
and brain samples. No blood sample was available to test if 
constitutive DNA also holds the permutation allele.
Findings in skeletal muscle included chronic inflammatory 
myopathy and rare rimmed vacuoles (Figure 1A). Examina-
tion of paraffin and frozen hematoxylin and eosin (H&E) sec-
tions showed marked variations in fiber size. Some round 
atrophic and angulated fibers and rare nuclear bags were 
seen. Internalized nuclei were increased. There was evidence 
TABLE 1. Case 1: medical history timeline
Year Summary of initial and follow-up visits Diagnostics / Interventions
1999 Primary motor neuron disease; foot drop, 
ataxia, falling
Spinal magnetic resonance imaging, metabolic, endocrine and heavy metal 
poisoning blood analyses (negative)
2001 Progressive lower extremity weakness Total hip replacement (not related to neurological symptoms)
2003 Develops upper extremity weakness Total hip replacement (not related to neurological symptoms)
2004 Clinical diagnosis of inclusion body myositis Shoulder replacement (not related to neurological symptoms); muscle biopsy, 
electron microscopy
2005 Septic embolic stroke following open fracture 
of the ankle; progressive weakness and ataxia
Supportive care; patient confined to bed
2012 Death due to respiratory failure
2013 Diagnosis of fragile X-associated tremor/ataxia 
syndrome
Postmortem analysis: 60 CGG repeats in the brain and skeletal muscles
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of myophagocytosis, degenerating and regenerating fibers, 
and moderate chronic inflammatory infiltrate surround-
ing and infiltrating muscle fibers with scattered necrotic 
fibers with a predominance of T cells (CD3 positive). Go-
mori Trichrome showed prominent interstitial fibrosis. Rare 
rimmed vacuoles were seen on Trichrome stain (Figure 1B). 
There was no evidence of ragged red fibers. Nicotinamide 
adenine dinucleotide (NADH) staining has revealed moth-
eaten and targetoid fibers. Succinate dehydrogenase stain 
showed patterns similar to NADH preparation.
Histopathological features (endomysial inflammatory infil-
trate and rare rimmed vacuoles) were consistent with di-
agnosis of IBM in appropriate clinical setting. Aggregates 
of TAR DNA-binding protein 43 (TDP-43) were observed in 
the cytoplasm of 5%-7% myofibers (Figure 1C), a finding 
supportive of IBM. Very rare nuclei contained round to oval 
TDP-34 positive inclusions, which morphologically resem-
ble those observed in brain specimens (Figure 1D). Sig-
nificance of such a finding is unclear. Tubulo-filamentous 
inclusions were not seen on the transmission electron mi-
croscopy. There was no evidence of perifascicular atrophy, 
making diagnosis of dermatomyositis unlikely. Congo red 
staining was negative.
Electron microscopic studies showed very rare, non-mem-
brane bound, non-filamentous inclusions (Figure 1E) and 
evidence of degeneration and regeneration of myofibers 
with moderate disarray of the contractile apparatus. The 
mitochondria appeared normal in number, internal struc-
ture, size, and distribution. There was no evidence of inclu-
sions in the cytoplasm or nucleus of myofibrils or endothe-
lial cells, and the vessels were unremarkable.
Postmortem neuropathological analysis revealed ubiquit-
in-positive intranuclear inclusions typical of FXTAS present 
in neurons and astrocytes (Figure 1F) in various regions of 
the brain including hippocampus, frontal cortex, and cer-
ebellum. The inclusions in each area of the brain were pres-
ent in different percentages (Table 2). Other brain findings 
FIGuRE 1. Histopathological and ultrastructural features in the skeletal muscle and brain of Case 1 showing chronic inflammatory 
myopathy and rimmed vacuoles along with neuronal and glial inclusions. A. Chronic inflammatory myopathy, hematoxylin and 
eosin (H&E) stain-400 × magnification. B. Black arrows are pointing to rimmed vacuoles, Trichrome Stain, 600 × oil magnification. 
C. Black arrow is pointing to TAR DNA-binding protein 43 (TDP-43) positive inclusions in cytoplasm of muscle fiber, H&E Stain, 
1000 × magnification (oil). D. Black arrows are pointing to TDP-43 positive inclusions in muscle nuclei, H&E stain, 1000 × magnifica-
tion (oil). E. Black arrow is pointing to rare muscle inclusions, transmission electron microscopy. F. H&E plus ubiquitin, 1000 × magni-
fication (oil) in brain tissue; black arrow points to neuronal inclusion and white arrow points to glial inclusion.
TABLE 2. Number of inclusions in astrocytes and neurons of 
various parts of patient brain for case 1
Inclusions (%)
Brain area astrocytes neurons
Hippocampus – dentate gyrus 12.41 2.39
Hippocampus – region CA1  8.78 3.64
Frontal cortex  8.40 5.00
Cerebellum – granule cell layer  7.50 2.23
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included mild atrophy and evidence of small vessel disease 
(arteriolosclerosis) in the white matter.
CASE REPORT 2
Patient 2, a Caucasian Australian female, was a known pre-
mutation carrier with 71 CGG repeats who had a son with 
FXS. She presented at age 61 with difficulty walking and 
was found to have a foot drop bilaterally (Table 3). Wasting 
of the small muscles in both hands was noted with wast-
ing and weakness in the distal lower limbs. Knee and ankle 
reflexes were absent. No sensory changes or fasciculations 
were seen. The clinical impression after neurological review 
was suggestive of anterior horn cell pathology. Nerve con-
duction studies and electromyography were performed, 
revealing an atypical mixed picture of myopathic and neu-
rogenic features suspicious of amyotrophic lateral sclerosis. 
A muscle biopsy revealed many necrotic and regenerat-
ing myofibers throughout the sample, but no endomysial 
chronic inflammatory cells were observed. Atrophic myofi-
bers and scattered hypertrophic myofibers were seen. Fo-
cal increases in interfiber connective tissue and lipids were 
present. Rimmed vacuoles were seen in many myofibers, 
highlighted with acid phosphatase; however, no ragged-
red myofibers were seen. Sarcolemmal immunostaining 
for major histocompatibility complex 1 was increased in all 
myofibers. Atrophic myofibers and scattered hypertrophic 
myofibers were seen. The COX negative myofibers were 
less than 1% of the total number. Moth-eaten myofibers 
were commonly seen. Histological diagnosis was consis-
tent with inclusion body myositis, and an unsuccessful trial 
of steroids (prednisone, 25 mg per day for two weeks) was 
undertaken. The patient was followed over the course of 5 
years, but her symptoms did not change significantly.
Five years after the diagnosis of IBM, a head tremor 
emerged. Walking and balance began to deteriorate more 
rapidly, with the patient noting numbness in the feet. Clini-
cally, there was evidence of sensory neuropathy in the low-
er limbs. In addition to a bilateral high-stepping gait, there 
was gait ataxia out of proportion to the chronic weakness 
associated with the pre-existing myopathy. She was subse-
quently diagnosed with FXTAS.
DISCuSSION
The two case reports presented here on the concomitant 
occurrence of FXTAS and sporadic IBM expand the aware-
ness of medical community on the complexity of clinical 
presentations of these two, seemingly pathogenically un-
related neurological disorders. Although the two patients 
were not managed by the same multidisciplinary team of 
health care professionals – case 1 was diagnosed in the 
USA and case 2 in Australia – the two countries abide by 
congruent medical practices and standards, which adds to 
the credibility of this joint report.
For case 1, it was not known at the time of the onset of 
patient’s illness that his granddaughter had the premu-
tation and learning problems. Following the diagnosis of 
the granddaughter, doctors did not consider the carrier 
status of the grandfather or reconsider his diagnosis until 
after death, when neuropathology studies demonstrated 
FXTAS, and appropriate genetic counseling was provided 
to the family. The foot drop as a first symptom is not seen 
in FXTAS, but the subsequent falling and ataxia are typi-
cal for FXTAS. The severity of the muscle weakness goes 
beyond what is usually seen in FXTAS, and case 1 never 
developed tremor, so the focus was on his muscle workup 
leading to the IBM diagnosis. However, muscle pain and 
weakness are common features of FXTAS (7,8). The pres-
ence of IBM is likely to increase the chance that FXTAS will 
develop in an aging carrier, as seen in case 2, reflecting 
the earlier observation in a cohort study of female carriers 
TABLE 3. Case 2: medical history timeline
Year Relevant medical and family history
1987 Son diagnosed with fragile X syndrome
1992 Diagnosed as a carrier with 71 CGG repeats
Year Summary of initial and follow-up visits Diagnostics / Interventions
2010 Clinical diagnosis of inclusion body myositis (IBM)
Foot drop bilaterally, wasting in distal lower limbs, absent 
knee and ankle reflexes
Nerve conduction studies, Electromyography and muscle 
biopsy
2010 No response to therapy Prednisone (25 mg/day) for 14-day trial
2010 – 2015 No significant change in the clinical status Observation
2015 Diagnosis of fragile X-associated tremor/ataxia syndrome
Head tremor, deterioration of walking and balance, numb-
ness in the feet
Clinical evidence of sensory neuropathy in the lower limbs
Gait ataxia not consistent with IBM
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with the premutation and immune-mediated disorders 
(IMD) (15,16).
It is not clear how the RNA-mediated events – collectively 
termed “RNA toxicity” (17-20) – rooted in increased expres-
sion levels of expanded FMR1 mRNA, as observed in per-
mutation carriers, predispose to IMDs. This predisposition 
could possibly involve either or both direct effects – pro-
tein sequestration of splicing factors interfering with their 
functions as regulator of alternative splicing and of the 
DROSHA/DGCR8 complex (a key player in miRNA biogen-
esis), or effects of mitochondrial dysfunction (16,21). The 
dysregulation of miRNAs is thought to predispose to IMD 
particularly in women with the premutation (16). In a study 
of 344 women with the premutation, 45% had at least one 
IMD involving multiple organs, a significantly higher rate 
than controls without the premutation. The most common 
problem was immune-mediated thyroid disorder in 24%, 
with fibromyalgia in 10%, and less common disorders, in-
cluding rheumatoid arthritis in 4%, Sjögren’s syndrome in 
2.6%, systemic lupus erythematosus in 2.0%, and multiple 
sclerosis in 2.0% (16). Although case 2 did not have a his-
tory of an immune-related disorder, she otherwise did ep-
idemiologically fit into the observation on the increased 
risk of developing IMD in aging female premutation car-
riers. For women with FXTAS older than 40 years of age, 
the proportion with IMD is estimated to be as high as 73% 
(16). The odds ratio for developing an IMD in women with 
FXTAS is 2.6% (95% CI 1.2 - 5.6, P = 0.015) compared with 
women carriers without FXTAS (16). IMDs are less common 
in males with the premutation, although case 1 is an ex-
ample of an IMD in an older man with FXTAS, and it is likely 
that both disorders began simultaneously. IMDs can also 
develop in those with the premutation because the cy-
tokine levels are lower in carriers as they age, making them 
more susceptible to both infections and IMDs (22). Because 
muscle pain, often leading to a diagnosis of fibromyalgia, is 
common, particularly in women with FXTAS (4,16,23), per-
haps assessment of creatine kinase levels is warranted as 
a screen for IBM, which may be more common than cur-
rently considered in those with FXTAS.
The histopathology of IBM shows endomysial chronic in-
flammation, invasion of non-necrotic muscle fibers by in-
flammatory cells, variable number of rimmed vacuoles, 
and 15-18-nm tubulofilaments on electron microscopy. 
Perifascicular atrophy is absent. Amyloid deposition in 
vacuolated muscle fibers can be demonstrated by Con-
go red staining. CD8-positive T cells are predominant 
and invade the non-necrotic fibers (9,10). Described 
histological findings may not all be present in patients 
with a clinical IBM (10,14).
Mitochondrial abnormalities are another pathological fea-
ture of IBM. These consist mainly of ragged red fibers and 
reduced cyclooxygenase activity (10). In the presented 
cases, mitochondrial disease was ruled out by electron mi-
croscopy and cyclooxygenase and succinate dehydroge-
nase activities. Further studies detecting mutations for mi-
tochondrial disease were not performed.
In summary, we described a review of symptoms and his-
tological analysis of two unrelated patients with FXTAS 
and concomitant, sporadic, clinically defined IBM. This is, 
to our knowledge, the first report of these two conditions 
presenting together, which expands our understanding of 
clinical symptoms and unusual presentations in patients 
with FXTAS.
FXTAS is reported as early as 30 years of age (24). However, it 
is known to occur later in life together with other disorders, 
including Alzheimer disease, Parkinsonism, and Prader-Wil-
li phenotype (3,7,25). IMDs are also often co-morbid with 
FXTAS (11,16,22). Presented cases emphasize the need to 
consider FXTAS with the onset of any neurological symp-
toms in aging premutation carriers, even when the presen-
tation is atypical. Documenting the presence of FXTAS in-
clusions clarifies the diagnosis of definite FXTAS, as laid out 
within the diagnostic criteria of this disorder (5,17).
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